OBSIDIAN THERAPEUTICS, INC. Research and Development Expense
OBSIDIAN THERAPEUTICS, INC. (OBX) reported Research and Development Expense of $21.55 million for the 3-month period ending 2026-06-30, per its S-1 filed 2026-08-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-28
- OBSIDIAN THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $21.55M, a 6.11% decline year-over-year.
- OBSIDIAN THERAPEUTICS, INC. research and development expense for the quarter ending 2025-06-30 was $22.95M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $21.55M S-1 · filed 2026-08-28 | $37.28M S-1 · filed 2026-08-28 | |
| 2025-12-31 | $86.11M S-1 · filed 2026-08-28 | ||
| 2025-06-30 | $22.95M S-1 · filed 2026-08-28 | $44.08M S-1 · filed 2026-08-28 | |
| 2024-12-31 | $73.19M S-1 · filed 2026-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |